Molecular Partners AG (XSWX:MOLN)
CHF 3.35 -0.04 (-1.18%) Market Cap: 110.11 Mil Enterprise Value: -60.67 Mil PE Ratio: 0 PB Ratio: 0.65 GF Score: 52/100

Molecular Partners AG at JPMorgan Healthcare Conference Transcript

Jan 16, 2020 / 05:00PM GMT
Release Date Price: CHF21.05 (-2.09%)
James Patrick Quigley
JP Morgan Chase & Co, Research Division - Analyst

Good morning, everybody. I'm James Quigley, European Pharma and Biotech Analyst from JPMorgan. It's my pleasure to welcome you to the Molecular Partners presentation. With us today is the CEO, Patrick Amstutz. After Patrick's presentation, we've got a breakout session in the Kent Room. So we come out here, head down the hall and go as far as you can, that's the Kent Room. So with that, over to you, Patrick.

Patrick Amstutz
Molecular Partners AG - Co-Founder, CEO, Member of Management Board & Director

Thanks, James, for the nice introduction. Thanks to everyone coming here. The weather today, it's not so good. So some have wet feet, special thanks to those waiting through the rivers out there. I want to also thank the people on the webcast listening in. As a Swiss company, we also have people, obviously, from also Switzerland, who will be listening in now. So at Molecular Partners, we worked very hard in the last year in-house, but also with our partners to align the stars for 2020

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot